Clinical Trials Logo

Dysbiosis clinical trials

View clinical trials related to Dysbiosis.

Filter by:

NCT ID: NCT05980884 Recruiting - Clinical trials for Gut Dysbiosis for TMAO Production From L-carnitine Consumption

Evaluation of Microbial-derived TMAO Production From Carnitine Intake by Testing Fecal Bbu Gene

Start date: July 24, 2023
Phase: N/A
Study type: Interventional

The risk of cardiovascular diseases from red meat consumption varies among individuals due to variations in gut microbiota. L-carnitine in red meat can be converted to TMAO in the body by certain bacteria. Not everyone experiences a significant increase in TMAO levels after consuming carnitine. Gut microbiota differences are observed between high and low TMAO producers. The presence of the bbu gene in gut microbiota is linked to TMAO production. This clinical research aims to determine if the bbu gene can predict TMAO levels after carnitine intake.

NCT ID: NCT05836155 Recruiting - Dysbiosis Clinical Trials

Evidence Based Probiotic Therapy of Proton Pump Inhibitor Induced Dysbiosis

EBP
Start date: July 10, 2023
Phase: N/A
Study type: Interventional

In this study the investigators aim to test whether an evidence based probiotic is able to revert proton pump inhibitor induced dysbiosis of the gut microbiome.

NCT ID: NCT05834010 Recruiting - Anorexia Nervosa Clinical Trials

Feasibility Study of Using Fecal Microbiota Transplants in Anorexia Nervosa

ReBoot
Start date: March 18, 2023
Phase: Early Phase 1
Study type: Interventional

The investigators hypothesize that prolonged undernutrition in anorexia nervosa alters the microbiome to a different steady-state (dysbiotic) composition that sustains the disease, even after returning to normal diet. The investigators propose that transplanting a fully ecologically functioning GM from a healthy donor, through a FMT, can reboot the gut-brain-axis, ameliorate symptoms and improve clinical outcomes. To approach this, in the challenging AN patient group, the investigators want to conduct a FMT feasibility/pilot study.

NCT ID: NCT05824819 Recruiting - Endometriosis Clinical Trials

Endometriosis and Peritoneal Dysbiosis

Start date: May 1, 2023
Phase: N/A
Study type: Interventional

Endometriosis is a complex clinical syndrome that impairs many aspects of a woman's life, characterized by a chronic estrogen-dependent inflammatory process, mainly affecting the pelvic organs, with ectopic presence of tissue analogous to the uterine mucosa (endometrium). Despite intensive research in the field of etiopathogenesis, its cause has not yet been determined, and treatment remains symptomatic. Endometriosis causes two main complications, i.e. pelvic pain syndrome and infertility. In recent years, thanks to the analysis of the human microbiome, it has become possible to deepen the knowledge of the physiological and pathological interactions between microorganisms inhabiting various body areas and the host. Bacteria may enter the peritoneal cavity in the mechanism of retrograde menstruation and translocate from the intestines, and then promote the development of local and systemic inflammation, leading to the symptoms of endometriosis. The study is to determine whether the presence of a specific intestinal, peritoneal and uterine microbiome correlates with endometriosis stage and whether its presence predisposes to increased pain or infertility. Concordance or divergence of bacterial populations inhabiting the peritoneal and uterine cavities could have clinical implications, i.e. the possibility of empirical antibiotic therapy in patients undergoing only endometrial aspiration biopsy and not opting for surgical treatment.

NCT ID: NCT05812157 Recruiting - Clinical trials for Axial Spondyloarthritis

Optimizing Anti-IL17 Antibody Therapy by Associating Fiber Supplementation to Correct Treatment-aggravated Gut Dysbiosis in Axial Spondyloarthritis - RESPOND-IL17

RESPOND-IL17
Start date: October 2, 2023
Phase: N/A
Study type: Interventional

Fiber is the main source of energy for colonic bacteria and its consumption favorably modifies the composition of the microbiota in only a few days. Their fermentation in the colon releases short-chain fatty acids (SCFAs). Clostridiales contain many strains producing SCFAs. These SCFAs can restore the intestinal barrier and promote certain anti-inflammatory cells, including regulatory T cells (Tregs), which are essential to the mechanisms in tolerance of the self. Fibers could therefore correct the intestinal abnormalities present in patients with axial spondyloarthritis (AxSpA) and aggravated by anti-IL-17 drugs and thus improve the therapeutic response to these treatments. The hypothesis is that dietary fiber will correct the dysbiosis in AxSpA patients and increase the release of SCFAs, which favorably modulate the immune response and improve AxSpA.

NCT ID: NCT05790564 Recruiting - Metabolic Syndrome Clinical Trials

Almonds to Improve Gut Health and Decrease Inflammation

Start date: November 17, 2022
Phase: N/A
Study type: Interventional

Almonds are a good source of beneficial compounds. This study will investigate if eating almonds everyday for 12 weeks can affect gut health and inflammation in persons with metabolic syndrome. Investigators will measure changes in metabolism, heart health, and the levels of vitamins and other compounds from almonds.

NCT ID: NCT05779449 Recruiting - Clinical trials for Patient Participation

Targeting the Gut Dysbiosis to Treat Inflammation-driven Synaptopathy in MS

Pre-Pro-MS
Start date: July 26, 2023
Phase: N/A
Study type: Interventional

Inflammatory synaptopathy is a prominent pathogenic process in multiple sclerosis (MS) induced by imbalanced immune system homeostasis. Its persistence causes excitotoxic neuronal damage, leading to motor and cognitive deficits. Although many advances have been made in MS treatment, the development of effective strategies for managing disease progression driven by excitotoxic synaptic dysfunctions is of great significance. Gut dysbiosis is commonly associated with both MS and obesity and high-fat diet (HFD) can exacerbate disease by acting on gut microbiota. Since gut microbiota can shape the immune response and brain functions, we propose to target gut dysbiosis by dietary supplementation of prebiotics and probiotics (Pre-Pro) to treat synaptopathy in both human and experimental model of MS, even when exacerbated by HFD. Overall, this project aims at unveiling the anti-inflammatory and neuroprotective pathways activated by Pre-Pro supplementation to modulate the immune-synaptic axis.

NCT ID: NCT05775341 Recruiting - Clinical trials for Surgical Site Infection

INtestinal Dysbiosis and TRanslocation of Bacteria in Patients Undergoing Surgery

INTRA
Start date: February 27, 2023
Phase:
Study type: Observational [Patient Registry]

The goal of this observational study is to contribute to a better understanding of the perioperative kinetics of intestinal microbial composition and association with surgical site infections. The main question this study aims to determine if: - Patients undergoing surgery develop transient intestinal dysbiosis - Such transient dysbiosis is associated with translocation to the systemic circulation and surgical site infection Patients undergoing elective abdominal surgery will be included prospectively. Informed consent will be obtained. From patients the following information and samples will be collected: - Perioperative: Baseline health data, nutrition data, measurement body composition, glucose monitoring - Intraoperatively: - Mucosal swabs - Blood from central venous catheter and portal vein - Mesenteric lymph node - Intestinal specimen - Bile - Subcutaneous biopsy - Postoperatively: - If a surgical site infection occurs samples from infected site

NCT ID: NCT05658263 Recruiting - Colon Cancer Clinical Trials

Bacterial Intestinal Gut Modification Around Cancer Surgery (BIG MACS) Diet

Start date: January 3, 2023
Phase: Early Phase 1
Study type: Interventional

The long-term study objective is to develop optimized nutritional therapies for surgery and test them in clinical practice. This pilot study will test a microbiome-optimization diet in colorectal cancer surgery patients. The study hypothesizes that the Bacterial Intestinal Gut Modification Around Cancer Surgery (BIG MACS) Diet will provide participants with increased microbiota accessible carbohydrates (MACs) to support the microbiome and improve outcomes.

NCT ID: NCT05633706 Recruiting - Ulcerative Colitis Clinical Trials

Evaluation of the SIMBA Capsule for Small Intestinal Dysbiosis

Start date: January 9, 2023
Phase:
Study type: Observational

The SIMBA Capsule is a small, single-use, ingestible capsule that allows for the non-invasive sampling of small bowel contents using purely mechanical means. The study will compare the microbial and metabolomics analysis from the sample collected with the capsule series, to same-participant symptom questionnaires and stool microbial analysis.